News
1h
Zacks Investment Research on MSNVKTX Initiates Phase 3 Study on Obesity Candidate VK2735Viking Therapeutics VKTX announced that it has initiated the phase III VANQUISH program, evaluating the subcutaneous (SC) ...
Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...
StockStory.org on MSN8h
5 Insightful Analyst Questions From Amgen’s Q1 Earnings CallAmgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...
Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...
The once-monthly drug is still under study but could provide added convenience and another option for patients.
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results